The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine ...

Shingrix has been administered in a two-step process. It involved combining two separate vials—a freeze-dried (lyophilized) powder containing the antigen, and a liquid adjuvant, by trained healthcare ...

A recent study suggests that certain immunizations may unexpectedly protect against cognitive decline, potentially reducing ...

The retrospective cohort study included more than 130,000 people in the US. It reveals that the shingles vaccine (called ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

The U.S. FDA has approved a prefilled syringe presentation of GSK plc’s SHINGRIX for the prevention of shingles.

The Food and Drug Administration (FDA) has approved a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

Patients with inflammatory arthritis would benefit from vaccination against herpes zoster, with the Shingrix vaccine showing a crude effectiveness of 50%.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.

Administering Shingrix previously required combining a lyophilised antigen with a liquid adjuvant from two separate vials.

US FDA approves GSK’s Shingrix in a prefilled syringe presentation for prevention of shingles: London, UK Friday, July 18, 2025, 09:00 Hrs [IST] GSK plc announced that the US Fo ...